EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Radiant Innovation (3373) fair value: what the stock is really worth

As of Oct 6, 2026: fair value of Radiant Innovation TWD 12.23, price TWD 15.95, upside -23.3%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0003373007

RI Thin data Oct 3, 2026

Radiant Innovation

3373 · TWO

Weak valuationQuality is weak on top of the rich price.

Quality 44/100
0.6% dividend yield · Token dividend
Fair value 12.23 TWD · Overvalued (−23.3%)
Weak Growth (revenue 5y −31.7 %/yr in TWD)
Loss-making · -8.6% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 10/100
Thin data
Watch Radiant Innovation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

62.23 TWD 15.80 TWD Fair Value 12.23 TWD May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 15.80 TWD – 62.23 TWD · fair‑value band 8.07 TWD – 15.29 TWD · the 15.95 TWD price screens above the 12.23 TWD fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Radiant Innovation in your weekly email

Every Wednesday you see whether Radiant Innovation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Radiant Innovation Inc. engages in the design and development of infrared technology products in Taiwan, Japan, and Germany. It offers medical infrared thermometers, including infrared ear, non-contact forehead, and multi-function thermometers, as well as probe cover; and CO2 monitors.

Show more

Radiant Innovation Inc. engages in the design and development of infrared technology products in Taiwan, Japan, and Germany. It offers medical infrared thermometers, including infrared ear, non-contact forehead, and multi-function thermometers, as well as probe cover; and CO2 monitors. The company also offers industrial infrared thermometers, infrared precision thermal imagers, infrared precision gas monitors and other components. Radiant Innovation Inc. was founded in 1989 and is headquartered in Hsinchu City, Taiwan.

Stock analysis

Radiant Innovation (3373) currently trades at 15.95 TWD, while our model-based Fair Value estimate is 12.23 TWD, 23.3% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 11.17 TWD per share, and 0 of the 3 models we run sit above the 15.95 TWD price.

Bear case: the Dividend Discount group reads lowest at 8.70 TWD, and 3 of the 3 models stay below the price. Evidence for this calculation is low.

Scenario range: 8.07 TWD (bear) to 15.29 TWD (bull), the price of 15.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Radiant Innovation reported revenue of 388M TWD in FY2025 versus 985M TWD in FY2021, a compound −20.8%/yr. Reported net income was −60.4M TWD in FY2025.

Key figures

Market cap 760M TWD (≈ $23.9M) · P/S ratio 1.85 · EPS (TTM) −0.7400 TWD · Dividend yield 0.6% · Net margin −15.6% · Return on equity −4.5% · Return on assets (EBIT) −2.3% · Operating margin −6.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −23%, 3373 screens richer than that median.

Fair Value models

Bear 8.07 TWD Fair Value 12.23 TWD Bull 15.29 TWD
Price 15.95 TWD · Upside -23.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM 7.98 TWD 8.70 TWD 9.79 TWD 69
DDM Multi-Stage 7.98 TWD 9.87 TWD 12.43 TWD 67
NCAV (Graham) 8.33 TWD 11.17 TWD 16.67 TWD 51
All 3 models by family
Dividend Discount
Gordon GGM 7.98 TWD 8.70 TWD 9.79 TWD 69
DDM Multi-Stage 7.98 TWD 9.87 TWD 12.43 TWD 67
Asset-Based
NCAV (Graham) 8.33 TWD 11.17 TWD 16.67 TWD 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 44/100

Of which business quality 44 · Market factors (momentum, volatility) 42

Profitability 8
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 91
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 8
Distance to the 52-week high (market factor)
Net Issuance 65
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
36.4% (2020) → −18.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

3373 screens overvalued: fair value 23% below the price. Compare with Abbott Laboratories, →

Compare Radiant Innovation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 335 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −23.3% · Below median
Profitability
Return on assets −4.6% · Below median
Net margin (TTM) −8.6% · Bottom 25%
Operating margin (TTM) −6.6% · Bottom 25%
Growth and dividend
Revenue growth 19.5% · Top 25%
Dividend yield (TTM) 0.6% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (TTM) 0.06× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)2 · sector 7
FUTURE (revenue growth)98 · sector 31
PAST (return on equity)0 · sector 16
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)13 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.10 $74.79 −25%
Medtronic plc MDT $86.38 $65.61 −24%
Stryker Corporation SYK $275.43 $302.97 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
DexCom, Inc DXCM $85.36 $93.90 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%
STERIS plc STE $208.93 $229.82 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Radiant Innovation · Fair Value
12.23 TWD −23%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Radiant Innovation Fair Value". https://www.fairvalue-calculator.com/stock/3373

Frequently asked questions

Is Radiant Innovation (3373) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 12.23 TWD versus a price of 15.95 TWD, about −23% upside (overvalued).
What is the fair value of 3373?
Our model-based fair value for Radiant Innovation is 12.23 TWD (as of Oct 3, 2026), built from audited fundamentals. The current price: 15.95 TWD.
What is the quality score of 3373?
Radiant Innovation has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Radiant Innovation (3373)?
Our model-based price target is the fair value of 12.23 TWD (as of Oct 3, 2026) from 3 valuation models. Cautious scenario 8.07 TWD, optimistic scenario 15.29 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Radiant Innovation stock forecast for 2026?
Our models put fair value at 12.23 TWD, about −23% upside versus a price of 15.95 TWD (overvalued). Cautious scenario 8.07 TWD, optimistic scenario 15.29 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Radiant Innovation (3373)?
Radiant Innovation reported trailing-twelve-month revenue of about 409M TWD (latest available figure, as of Oct 3, 2026).
Does Radiant Innovation pay a dividend?
Radiant Innovation currently shows a dividend yield of about 0.63% relative to its recent price (as of Oct 3, 2026).
What is the intrinsic value of Radiant Innovation (3373)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Radiant Innovation it is 12.23 TWD per share (as of Oct 3, 2026), against a price of 15.95 TWD. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Radiant Innovation stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 3373 trades above its calculated fair value: price 15.95 TWD, fair value 12.23 TWD, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3373?
No. The price is what the market pays today (15.95 TWD); the fair value is what the company's own numbers justify (12.23 TWD). For Radiant Innovation the two are 3.72 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Radiant Innovation worth?
The market values Radiant Innovation at about 760M TWD (market capitalisation, as of Oct 3, 2026). Per share that is 15.95 TWD; our models calculate a fair value of 12.23 TWD per share.
What do the bullish and bearish scenarios say about 3373?
Our models span a range for Radiant Innovation: cautious scenario 8.07 TWD, base 12.23 TWD, optimistic 15.29 TWD per share (as of Oct 3, 2026, price 15.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Radiant Innovation (3373)?
Balance-sheet figures for Radiant Innovation (as of Oct 3, 2026): return on equity −4.5%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 3373 from its 52-week high?
Radiant Innovation trades at 15.95 TWD, about 23% below its 52-week high of 20.65 TWD and 1% above the low of 15.80 TWD (as of Oct 6, 2026). Distance from the high says nothing about value: that is what the fair value of 12.23 TWD is for.
Which stocks are comparable to Radiant Innovation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Radiant Innovation stock attractive at the current price?
The data as of Oct 3, 2026: price 15.95 TWD, calculated fair value 12.23 TWD (−23%), Quality Score 44/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3373 calculated?
We run Radiant Innovation through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12.23 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. Radiant Innovation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Radiant Innovation (3373)?
The closing price on Oct 6, 2026 was 15.95 TWD. Our model-based fair value is 12.23 TWD, about −23% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Radiant Innovation right now?
The price sits above even our optimistic bull case (15.29 TWD). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (8.07 TWD to 15.29 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Radiant Innovation

How large is the market capitalisation of Radiant Innovation (3373)?
The market capitalisation of Radiant Innovation is 760M TWD (≈ $23.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Radiant Innovation (3373)?
The price-to-sales ratio of Radiant Innovation is 1.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Radiant Innovation (3373)?
Earnings per share at Radiant Innovation are −0.7400 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Radiant Innovation (3373)?
The dividend yield of Radiant Innovation is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Radiant Innovation (3373)?
The net margin of Radiant Innovation is −15.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Radiant Innovation (3373)?
The return on equity (ROE) of Radiant Innovation is −4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Radiant Innovation (3373)?
On an EBIT basis the return on assets of Radiant Innovation is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Radiant Innovation (3373)?
The operating margin of Radiant Innovation is −6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Radiant Innovation (3373)?
Revenue at Radiant Innovation is growing +19.5% versus a year earlier (3y avg −11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Radiant Innovation (3373)?
Earnings per share at Radiant Innovation are growing −74.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Radiant Innovation (3373) generate?
The free cash flow of Radiant Innovation is −5.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Radiant Innovation in the live analysis

One click puts Radiant Innovation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.